Allogene Therapeutics(US:ALLO)2025-11-06 21:28Financial Performance - Allogene Therapeutics reported a net loss of $41.4 million for Q3 2025, or $0.19 per share, compared to a net loss of $66.3 million in Q3 2024[15] - Total operating expenses for Q3 2025 were $44.9 million, a decrease from $71.8 million in Q3 2024[19] - The company expects a decrease in cash, cash equivalents, and investments of approximately $150 million for 2025[11] - GAAP operating expenses for 2025 are projected to be approximately $230 million, including an estimated non-cash stock-based compensation expense of $45 million[11] Research and Development - Research and development expenses for Q3 2025 were $31.2 million, down from $44.7 million in Q3 2024[19] - The pivotal Phase 2 ALPHA3 trial with cema-cel is expected to conduct a futility analysis in the first half of 2026, focusing on minimal residual disease (MRD) conversion rates[6] - The Phase 1 RESOLUTION trial with ALLO-329 is exploring treatment regimens that may reduce or eliminate lymphodepletion, with proof-of-concept data anticipated in the first half of 2026[9] - Allogene's ALLO-316 trial in renal cell carcinoma has shown early signs of efficacy and tolerability, with plans for the next phase ongoing[10] Cash Position - The company ended Q3 2025 with $277.1 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2027[11] - The company has over 50 active clinical sites in the U.S. and Canada for the ALPHA3 trial, with additional sites in Australia and South Korea expected to open in early 2026[5]